[Continuation 50. Type 2 diabetes: possibilities and limitations of pharmacological therapy].
D017485:1-Deoxynojirimycin / Q000031:analogs & derivatives; D020909:Acarbose / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D000368:Aged; D001786:Blood Glucose / Q000032:analysis; D002219:Carbamates / Q000008:administration & dosage / Q000627:therapeutic use; D000075202:Contraindications; D003510:Cyclohexanes / Q000008:administration & dosage / Q000627:therapeutic use; D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000150:complications / Q000188:drug therapy* / Q000453:epidemiology; D004359:Drug Therapy, Combination; D004791:Enzyme Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use; D005215:Fasting; D005500:Follow-Up Studies; D005858:Germany / Q000453:epidemiology; D005944:Glucosamine / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D005905:Glyburide / Q000008:administration & dosage / Q000627:therapeutic use; D006442:Glycated Hemoglobin / Q000032:analysis; D065089:Glycoside Hydrolase Inhibitors; D006801:Humans; D007003:Hypoglycemia / Q000139:chemically induced; D007004:Hypoglycemic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D050112:Imino Pyranoses; D007328:Insulin / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D008687:Metformin / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D008875:Middle Aged; D000077715:Nateglinide; D009765:Obesity / Q000150:complications; D010349:Patient Compliance; D010649:Phenylalanine / Q000008:administration & dosage / Q000031:analogs & derivatives / Q000627:therapeutic use; D000077205:Pioglitazone; D010880:Piperidines / Q000008:administration & dosage / Q000627:therapeutic use; D017410:Practice Guidelines as Topic; D012307:Risk Factors; D000077154:Rosiglitazone; D013453:Sulfonylurea Compounds / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D045162:Thiazolidinediones / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D013997:Time Factors
D017485:1-Deoxynojirimycin; D020909:Acarbose; D001786:Blood Glucose; D002219:Carbamates; D003510:Cyclohexanes; D004791:Enzyme Inhibitors; D005944:Glucosamine; D005905:Glyburide; D006442:Glycated Hemoglobin; D065089:Glycoside Hydrolase Inhibitors; D007004:Hypoglycemic Agents; D050112:Imino Pyranoses; D007328:Insulin; D008687:Metformin; D000077715:Nateglinide; D010649:Phenylalanine; D000077205:Pioglitazone; D010880:Piperidines; D000077154:Rosiglitazone; D013453:Sulfonylurea Compounds; D045162:Thiazolidinediones; C045621:miglitol; C072379:repaglinide
Zur 50. Folge. Typ 2 Diabetes: Möglichkeiten und Grenzen der pharmakologischen Therapie.